Registry for patients with myeloid neoplasms
Official title: A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients With Myeloid Neoplasms
Run by University Hospital Heidelberg · NCT05074316 · Data updated 2026-11-12
This study is creating a detailed registry for people with myeloid neoplasms to gather important information that can help improve treatment and care for these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | CAR-T, immunotherapy, radiation |
| Locations | 1 site (Heidelberg, Baden-Wurttemberg) |
| Status | Recruiting |
| Started | March 10, 2020 |
| Main results expected | July 31, 2030 |
| Study ends | December 31, 2032 |
| Registry record updated | March 25, 2025 |
| Trial ID | NCT05074316 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a suspected or confirmed diagnosis of myeloid neoplasms.
✕Probably not a fit
Patients with severe neurological or psychiatric disorders that prevent them from providing informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Myeloid Neoplasms Biology and Outcome Project (MyBOP) is designed to create a comprehensive registry for patients diagnosed with myeloid neoplasms. This observational study will collect clinical data, biological samples, socio-demographic information, and patient-reported outcomes to enhance the understanding of these conditions. By integrating long-term follow-up data, the project aims to improve evidence-based clinical management and facilitate access to personalized treatment options through clinical studies. The study also seeks to ensure quality assurance among participating centers by comparing clinical outcomes with existing published data.
Why it matters
Potential benefit: If successful, this project could lead to improved clinical management and personalized treatment options for patients with myeloid neoplasms.
How similar studies have gone: Other studies focusing on registry-based approaches for myeloid neoplasms have shown promise in improving patient outcomes and understanding disease progression.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected or proven diagnosis of Myeloid Neoplasms according to the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues * Age ≥18 years * Ability to understand the nature and individual consequences of the registry * Written informed consent * Subjects who are physically or mentally capable of giving consent Exclusion Criteria: Severe neurological or psychiatric disorder interfering with the ability to give written informed consent
Where it's running
-
UHHeidelberg
Heidelberg, Baden-Wurttemberg, Germany Recruiting
Study contacts
- Principal investigator: Richard F Schlenk, M.D. — University Hospital Heidelberg, Department of Internal Medicine V, German Cancer Research Center
- Study coordinator: Editha Gnutzmann, M.A.
- Email: editha.gnutzmann@med.uni-heidelberg.de
- Phone: +49 6221 56 36235
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Choosing the Right Treatment Intensity for Adults with Acute Myeloid Leukemia and Myeloid Neoplasms
This study tests whether a computer-guided randomization can help decide if a patient should receive higher- or lower-intensity chemotherapy when they’re not clearly fit, to see which approach is more helpful for adults with AML or related myeloid cancers.
-
Lower versus higher hemoglobin thresholds for red blood cell transfusions in adults with high-grade myeloid cancers or B-cell ALL/lymphoma
This will see if giving transfusions only when hemoglobin drops to 7 g/dL instead of 9 g/dL affects quality of life and physical functioning for adults receiving intensive chemotherapy or allogeneic stem cell transplant for high-grade myeloid cancers or B-cell ALL/lymphoma.
-
Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients
This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.
-
Mobile health exercise program for older adults with myeloid neoplasms
This study is testing a mobile health exercise program to see if it can help older adults with myeloid neoplasms feel better and maintain their physical abilities while they are receiving chemotherapy.
-
Combining venetoclax with chemotherapy for treating acute myeloid leukemia
This study is testing if combining a drug called venetoclax with a specific chemotherapy can help people with acute myeloid leukemia and high-grade myeloid neoplasms feel better and fight their cancer more effectively.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.